China
Africa
Explore chapters and articles related to this topic
Tablet Coating Formulations
Published in Sarfaraz K. Niazi, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition, 2019
Solid dosage forms are frequently coated for varied purposes, including the following: Mask taste and smell.Offer protection from the environment.Provide protection from gastric acid (enteric coating).Make dose easy to swallow.Provide identification.Add esthetic appeal.Hide surface defects.
The Role of Polymers in Solid Oral Dosage Forms
Published in Ijeoma F. Uchegbu, Andreas G. Schätzlein, Polymers in Drug Delivery, 2006
Richard A. Kendall, Abdul W. Basit
Early attempts at enteric coating used natural materials such as shellac, gelatin, and keratin. Such materials, being of natural origin, suffered problems with batch-to-batch variability, and for the purposes of enteric coating, they are of historical significance only.
Stimuli-Responsive Polymer Coatings
Published in Sanjay Mavinkere Rangappa, Jyotishkumar Parameswaranpillai, Suchart Siengchin, Polymer Coatings, 2020
Fabrice Ofridam, Mohamad Tarhini, Waisudin Badri, Wei Liao, Noureddine Lebaz, Émilie Gagnière, Denis Mangin, Emilie Dumas, Sami Ghnimi, Abdelhamid Errachid El Salhi, Adem Gharsallaoui, Hatem Fessi, Abdelhamid Elaissari
Enteric coating or enteric capsule is a polymer layer added to drug tablets to increase the efficiency of the drug by protecting the tablet from early degradation [112]. Two types of enteric coatings are popular. One is based on copolymer of methacrylic monomers, and the other is based on ethylcellulose. Both types have a pH-sensitive profile. They are hydrophobic at gastric pH that restricts the release of the drug, and they become hydrophilic at intestinal pH allowing the drug to be released in the intestines, thereby protecting it from gastric degradation. This will improve the efficiency of oral drug delivery [111]. This characteristic was exploited to deliver peptides and protein through oral route. Mucoadhesive intestinal patches loaded with insulin were coated with ethylcellulose to secure a safe passage for a therapeutic dose of insulin through the digestive system to be released near intestinal mucosa. In vivo results showed that these patches induced dose-dependent hypoglycaemia in normal rats with a maximum drop in blood glucose levels of 75% [93]. In another study, pH-sensitive chitosan and poly(ɣ-glutamic acid) nanoparticles were loaded with insulin, freeze-dried, and coated with Eudragit® S100 and Eudragit®L100-55 capsules. After in vivo oral administration in diabetic rats, it was found that intestinal absorption of insulin was enhanced and the relative bioavailability was about 20% [94]. Light-responsive polymer coating was also used for insulin delivery. Gold nanoparticles loaded with insulin and coated with hydrophobic ethylcellulose were developed. By applying near-infrared irradiation, gold nanoparticles are heated, which led to reversible collapse of the polymer network, resulting in the formation of porous structure, and therefore, a rapid diffusion of insulin was allowed. It was also found that by controlling the irradiation, insulin dosing in diabetic rats can be controlled [95].
Duloxetine hydrochloride enteric-coated pellets in capsules with delayed release: formulation and evaluation
Published in Smart Science, 2023
Ramya Krishna Nakkala, Balaji Maddiboyina, Shanmukha Chakravarthi Bolisetti, Harekrishna Roy
Duloxetine hydrochloride is an acid-labile drug, which degrades when exposed to the stomach’s acidic environment. The drug’s enteric coating is preserved to inhibit its release in the stomach and enhance its release in the intestine. The drug was placed onto the sugar sphere using HPMC E5 binder. In addition, the study reveals that covering enteric-coated pellets with opadry AMB OY-28900 prevents moisture absorption and enhances stability, hence extending the drug’s shelf life. According to the similarity factor, the enteric-coated pellets of DHCl formulation F7 were optimized since they had a similar release profile to the innovator. The results indicate that the best formulation of duloxetine hydrochloride delayed-release pellets in capsules 60 mg (F7) was used to obtain appropriate drug levels in the intestine. As a result of in-vitro drug release and stability investigations, additional in-vivo testing is required to guarantee bioequivalence. Additionally, the new formulation can be pipelined for industrial production and used in place of the commercially available innovator capsule.